Today the European Medicines Agency (EMA) has started to evaluate an application presented by the Pfizer / BioNTech pharmaceutical companies for the injection of the third dose of the COVID-19 vaccine 6 months after the second vaccine in those over 16 years of age, and expects to announce its findings “in the coming weeks.”
The third dose of the covid vaccine
For the moment, Health has postponed the third dose debate of the covid vaccine in residences. And that, despite the fact that 6 autonomous communities have asked to be able to re-immunize the elderly in these centers against the coronavirus. The autonomous communities are: Castilla la Mancha, Andalusia, Valencia, Aragon, La Rioja and Murcia.
On Brussels, the Committee for Human Medicines (CHMP) will analyze, in an accelerated evaluation, the data presented by Pfizer, including the results of an ongoing clinical trial in which about 300 adults with healthy immune systems received a booster dose of the SARS-CoV-2 coronavirus vaccine approximately six months after the current recommended schedule.
The Comirnaty booster dose (trade name of Pfizer’s covid vaccine) would be intended for people who have already received both injections, that is, they have “completed their primary vaccination”, and would have the objective of “restoring protection after it has diminished” by the passage of time.
The EMA has not set a date to conclude this evaluation of the third dose of the covid vaccine, which could end in the recommendation of an “additional dose” as part of the primary vaccination of immunosuppressed people, in an attempt to develop the necessary protection against him coronavirus Covid-19.
–
